The global market for Crohn’s disease (CD) treatment is on a significant growth trajectory, projected to reach approximately USD 17.80 billion by the end of 2033. This substantial increase, up from USD 11.68 billion in 2023, reflects a compound annual growth rate (CAGR) of 4.3%, according to a comprehensive report by Future Market Insights.
The burgeoning prevalence of Crohn’s disease and ulcerative colitis across the globe serves as the primary driver of this market expansion. As public awareness and medical understanding of these chronic inflammatory bowel diseases continue to rise, so does the demand for effective treatment options. This trend is expected to significantly bolster the market over the next decade.
Ignite Your Growth: Unveil the Future Opportunities in the Crohn’s Disease (CD) Treatment Market – Get Your Sample Report
With advancements in medical research and pharmaceutical innovations, the treatment landscape for Crohn’s disease is evolving rapidly. Patients are increasingly seeking newer, more effective therapies that offer better management of symptoms and improved quality of life. This heightened demand is prompting pharmaceutical companies to invest heavily in research and development, aiming to introduce novel therapeutic solutions that can address the unmet needs of patients.
The Future Market Insights report emphasizes the role of cutting-edge biologics and biosimilars, alongside conventional therapies, in shaping the future of Crohn’s disease treatment. As these advanced treatments become more accessible, they are likely to contribute to the overall growth of the market.
In addition to the rising patient population, other factors such as improved diagnostic capabilities, growing healthcare infrastructure, and increased healthcare spending are also playing a pivotal role in the market’s expansion. As healthcare systems around the world become more equipped to diagnose and manage Crohn’s disease, the market is poised for continued growth.
Industry experts anticipate that the market’s steady growth will also drive strategic partnerships and collaborations among key players, fostering innovation and improving patient outcomes. The Future Market Insights report serves as a valuable resource for stakeholders, providing insights into market trends, growth drivers, and potential challenges.
Key Takeaways from the Market Study:
- The Crohn’s disease treatment market expanded historically between 2018 and 2022 at a CAGR of 3.2%.
- More than $11.2 billion is presently spent on treating Crohn’s disease globally.
- Immunomodulators are predicted to lead the medication type sector in 2023 with a 53% revenue share.
- The hospital pharmacy sector by distribution channel will maintain the second-largest segment during the anticipated period, with a global market share of 27.3% in 2023.
- From 2023 to 2033, the North American region is expected to expand at a constant CAGR of 4.9%.
- From 2023 to 2033, the Asia Pacific Crohn’s Disease Treatment Market is anticipated to expand at a stable CAGR of 3.6%.
“The increasing prevalence of ulcerative colitis and Crohn’s disease along with innovative pipeline of biological therapies and medications are expected to accelerate the growth during the forecast period,” comments a Future Market Insights analyst.
Enhance Your Business Outcomes with the Strategic Insights from A Full Report Analysis
Competitive Landscape:
Some of the top players in the global intraocular lymphoma disease market are:
- Abbvie Inc.
- Celgene Corporation
- Genetech
- Johnson & Johnson
- Pfizer
- Prometheus Laboratories Inc. (Nestle)
- Salix Pharmaceuticals Inc.
- Takeda’s Pharmaceutical Ltd
- Janssen Pharmaceuticals
- Biogen
- AstraZeneca
Some of the recent developments in this domain are:
- In 2022, AbbVie said that SKYRIZI® (risankizumab-rzaa) has received FDA approval to be used in the management of moderately to highly active Crohn’s disease. The interleukin-23 (IL-23) inhibitor SKYRIZI binds to the p19 component of IL-23 to specifically inhibit it. A variety of chronic immune-mediated disorders, including Crohn’s disease, are suspected to be related to IL-23, a cytokine implicated in inflammatory processes.
- Tiziana Life Sciences, a biotechnology firm that enables breakthrough immunotherapies through innovative modes of monoclonal antibody administration, announced the start of a Phase 1b clinical study in 2022 to test foralumab enteric-coated capsules orally delivered in people who have mild to moderate Crohn’s Disease (CD). A unique method of inducing an anti-inflammatory immune reaction by site-targeted immunomodulation in the intestine is oral administration of foralumab.
Key Segments Covered in the Crohn’s Disease Treatment Market Report:
By Drug Type:
- Antibiotics
- Amino Salicylates
- Corticosteroids
- Immunomodulators
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
